Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cytokinetics Inc (NASDAQ:CYTK)

16.40
Delayed Data
As of Apr 28
 -0.60 / -3.53%
Today’s Change
7.18
Today|||52-Week Range
17.20
+34.98%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$709.2M

Company Description

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Contact Information

Cytokinetics, Inc.
280 East Grand Avenue
South San Francisco California 94080
P:(650) 624-3000
Investor Relations:
(650) 624-3060

Employees

Shareholders

Individual stakeholders7.48%
Other institutional41.21%
Mutual fund holders31.16%

Top Executives

Robert I. BlumPresident, Chief Executive Officer & Director
Barabari Sharon A. SurreyChief Financial Officer, Secretary & Executive VP
Fady Ibraham MalikExecutive Vice President-Research & Development
Andy WolffChief Medical Officer & Senior Vice President
Bonnie A. CharpentierSenior VP-Regulatory Affairs & Compliance